The Medical Letter on Drugs and Therapeutics
A New Conjugate Meningococcal Vaccine (Menveo)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Menveo (Novartis), a new quadrivalent conjugated polysaccharide vaccine, for protection against disease caused by Neisseria meningitidis in people 11-55 years old.

THE DISEASE — About 1000-2000 cases of meningococcal disease occur annually in the US. The case fatality rate has remained higher than 10% for meningitis and up to 40% for meningococcemia. Among survivors, approximately 20% sustain permanent disabilities such as hearing loss, limb amputations and neurological abnormalities. Rates of meningococcal disease are highest in infancy, but a second peak occurs in adolescents and young adults, particularly college freshmen living in dormitories.1

SEROGROUPS — Five major serogroups of N. meningitidis, A, B, C, Y and W-135, cause most invasive disease. Serogroup A is the leading cause of epidemic meningitis worldwide, especially ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Conjugate Meningococcal Vaccine (Menveo)
Article code: 1343b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian